{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:27Z","timestamp":1790298207378,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00243720"],"award-info":[{"award-number":["RS-2023-00243720"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kukje Pharmaceuticals Co., Ltd","award":["I2203241"],"award-info":[{"award-number":["I2203241"]}]},{"DOI":"10.13039\/501100015825","name":"Korea University Anam Hospital","doi-asserted-by":"publisher","award":["K2330791"],"award-info":[{"award-number":["K2330791"]}],"id":[{"id":"10.13039\/501100015825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53334-5","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:52:38Z","timestamp":1779133958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of immediate therapeutic effects of 3% diquafosol and 2% rebamipide in dry eye disease: a prospective, randomized, paired-eye trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Myung-Sun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsub","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"53334_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig, J. P. et al. TFOS DEWS II definition and classification report. Ocul. Surf. 15, 276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008 (2017).","journal-title":"Ocul. Surf."},{"key":"53334_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/02713683.2016.1233986","volume":"42","author":"KE Choi","year":"2017","unstructured":"Choi, K. E., Song, J. S., Kang, B., Eom, Y. & Kim, H. M. Immediate effect of 3% diquafosol ophthalmic solution on tear MUC5AC concentration and corneal wetting ability in normal and experimental keratoconjunctivitis sicca rat models. Curr. Eye Res. 42, 666\u2013671. https:\/\/doi.org\/10.1080\/02713683.2016.1233986 (2017).","journal-title":"Curr. Eye Res."},{"key":"53334_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tvjl.2014.05.022","volume":"202","author":"K Terakado","year":"2014","unstructured":"Terakado, K. et al. Conjunctival expression of the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution in dogs. Vet. J. 202, 48\u201352. https:\/\/doi.org\/10.1016\/j.tvjl.2014.05.022 (2014).","journal-title":"Vet. J."},{"key":"53334_CR4","doi-asserted-by":"publisher","first-page":"C595","DOI":"10.1152\/ajpcell.2001.281.2.C595","volume":"281","author":"Y Li","year":"2001","unstructured":"Li, Y. et al. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am. J. Physiol. Cell Physiol. 281, C595-602. https:\/\/doi.org\/10.1152\/ajpcell.2001.281.2.C595 (2001).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"53334_CR5","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1167\/iovs.13-13128","volume":"54","author":"T Ohguchi","year":"2013","unstructured":"Ohguchi, T. et al. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest. Ophthalmol. Vis. Sci. 54, 7793\u20137802. https:\/\/doi.org\/10.1167\/iovs.13-13128 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"53334_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3341\/kjo.2023.0076","volume":"38","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. et al. New Korean guidelines for the diagnosis and management of dry eye disease. Korean J. Ophthalmol. 38, 156\u2013163. https:\/\/doi.org\/10.3341\/kjo.2023.0076 (2024).","journal-title":"Korean J. Ophthalmol."},{"issue":"Suppl 1","key":"53334_CR7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/icl.0000000000000643","volume":"46","author":"K Tsubota","year":"2020","unstructured":"Tsubota, K. et al. A new perspective on dry eye classification: Proposal by the Asia Dry Eye Society. Eye Contact Lens: Sci. Clin. Pract. 46(Suppl 1), S2-s13. https:\/\/doi.org\/10.1097\/icl.0000000000000643 (2020).","journal-title":"Eye Contact Lens: Sci. Clin. Pract."},{"key":"53334_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45475-7","volume":"9","author":"S Fukuoka","year":"2019","unstructured":"Fukuoka, S. & Arita, R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: A randomized clinical study. Sci. Rep. 9, 9091. https:\/\/doi.org\/10.1038\/s41598-019-45475-7 (2019).","journal-title":"Sci. Rep."},{"key":"53334_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura, E., Tsubota, K., Watanabe, H. & Ohashi, Y. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br. J. Ophthalmol. 96, 1310\u20131315. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301448 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"53334_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/ICO.0b013e3182930b1d","volume":"32","author":"S Shimazaki-Den","year":"2013","unstructured":"Shimazaki-Den, S., Iseda, H., Dogru, M. & Shimazaki, J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea 32, 1120\u20131125. https:\/\/doi.org\/10.1097\/ICO.0b013e3182930b1d (2013).","journal-title":"Cornea"},{"key":"53334_CR11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s12325-014-0162-4","volume":"31","author":"M Yamaguchi","year":"2014","unstructured":"Yamaguchi, M. et al. Clinical usefulness of diquafosol for real-world dry eye patients: A prospective, open-label, non-interventional, observational study. Adv. Ther. 31, 1169\u20131181. https:\/\/doi.org\/10.1007\/s12325-014-0162-4 (2014).","journal-title":"Adv. Ther."},{"key":"53334_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.18240\/ijo.2021.10.07","volume":"14","author":"Y Eom","year":"2021","unstructured":"Eom, Y. & Kim, H. M. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: A multicenter prospective observational study. Int. J. Ophthalmol. 14, 1518\u20131526. https:\/\/doi.org\/10.18240\/ijo.2021.10.07 (2021).","journal-title":"Int. J. Ophthalmol."},{"key":"53334_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2015.12.002","volume":"163","author":"DH Park","year":"2016","unstructured":"Park, D. H., Chung, J. K., Seo, D. R. & Lee, S. J. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: A randomized controlled trial. Am. J. Ophthalmol. 163, 122-131.e122. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.002 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"53334_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/opth.S69486","volume":"9","author":"S Koh","year":"2015","unstructured":"Koh, S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clin. Ophthalmol. 9, 865\u2013872. https:\/\/doi.org\/10.2147\/opth.S69486 (2015).","journal-title":"Clin. Ophthalmol."},{"key":"53334_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/02713683.2013.834939","volume":"39","author":"S Itoh","year":"2014","unstructured":"Itoh, S., Itoh, K. & Shinohara, H. Regulation of human corneal epithelial mucins by rebamipide. Curr. Eye Res. 39, 133\u2013141 (2014).","journal-title":"Curr. Eye Res."},{"key":"53334_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","volume":"23","author":"H Urashima","year":"2004","unstructured":"Urashima, H., Okamoto, T., Takeji, Y., Shinohara, H. & Fujisawa, S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-Acetylcysteine-treated in vivo model. Cornea 23, 613\u2013619. https:\/\/doi.org\/10.1097\/01.ico.0000126436.25751.fb (2004).","journal-title":"Cornea"},{"key":"53334_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajo.2017.06.016","volume":"181","author":"K Kato","year":"2017","unstructured":"Kato, K. et al. Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and Rebamipide: A randomized trial. Am. J. Ophthalmol. 181, 26\u201336. https:\/\/doi.org\/10.1016\/j.ajo.2017.06.016 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"53334_CR18","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3892\/etm.2017.4390","volume":"13","author":"S Kase","year":"2017","unstructured":"Kase, S., Shinohara, T., Kase, M. & Ishida, S. Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva. Exp. Ther. Med. 13, 3516\u20133522 (2017).","journal-title":"Exp. Ther. Med."},{"key":"53334_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098390","volume":"9","author":"R Arakaki","year":"2014","unstructured":"Arakaki, R. et al. Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sj\u00f6gren\u2019s syndrome. PLoS ONE 9, e98390 (2014).","journal-title":"PLoS ONE"},{"key":"53334_CR20","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","volume":"120","author":"S Kinoshita","year":"2013","unstructured":"Kinoshita, S. et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology 120, 1158\u20131165 (2013).","journal-title":"Ophthalmology"},{"key":"53334_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ajo.2013.11.010","volume":"157","author":"S Kinoshita","year":"2014","unstructured":"Kinoshita, S. et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am. J. Ophthalmol. 157, 576-583.e571. https:\/\/doi.org\/10.1016\/j.ajo.2013.11.010 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"53334_CR22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4103\/ijo.Ijo_2586_22","volume":"71","author":"K Jain","year":"2023","unstructured":"Jain, K., Jaju, M. & Yadav, D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian J. Ophthalmol. 71, 1598\u20131602. https:\/\/doi.org\/10.4103\/ijo.Ijo_2586_22 (2023).","journal-title":"Indian J. Ophthalmol."},{"key":"53334_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03004-1","volume":"23","author":"Y Eom","year":"2023","unstructured":"Eom, Y. et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: A multicenter randomized trial. BMC Ophthalmol. 23, 343. https:\/\/doi.org\/10.1186\/s12886-023-03004-1 (2023).","journal-title":"BMC Ophthalmol."},{"key":"53334_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13121-9","volume":"7","author":"J Shimazaki","year":"2017","unstructured":"Shimazaki, J. et al. A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers. Sci. Rep. 7, 15210. https:\/\/doi.org\/10.1038\/s41598-017-13121-9 (2017).","journal-title":"Sci. Rep."},{"key":"53334_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/jop.2016.0096","volume":"33","author":"H Kobashi","year":"2017","unstructured":"Kobashi, H., Kamiya, K. & Shimizu, K. Randomized comparison between rebamipide ophthalmic suspension and diquafosol ophthalmic solution for dry eye after penetrating keratoplasty. J. Ocul. Pharmacol. Ther. 33, 13\u201318. https:\/\/doi.org\/10.1089\/jop.2016.0096 (2017).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63784-4","volume":"14","author":"Y Jin","year":"2024","unstructured":"Jin, Y., Seo, K. Y. & Kim, S. W. Comparing two mucin secretagogues for the treatment of dry eye disease: A prospective randomized crossover trial. Sci. Rep. 14, 13306. https:\/\/doi.org\/10.1038\/s41598-024-63784-4 (2024).","journal-title":"Sci. Rep."},{"key":"53334_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1089\/jop.2016.0092","volume":"33","author":"Y Hori","year":"2017","unstructured":"Hori, Y. et al. Comparison of short-term effects of Diquafosol and Rebamipide on Mucin 5AC Level on the Rabbit Ocular Surface. J. Ocul. Pharmacol. Ther. 33, 493\u2013497. https:\/\/doi.org\/10.1089\/jop.2016.0092 (2017).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/eye.2016.54","volume":"30","author":"N Yokoi","year":"2016","unstructured":"Yokoi, N., Kato, H. & Kinoshita, S. The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sj\u00f6gren\u2019s syndrome: A pilot study. Eye (Lond) 30, 857\u2013864. https:\/\/doi.org\/10.1038\/eye.2016.54 (2016).","journal-title":"Eye (Lond)"},{"key":"53334_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020367","author":"M Uchino","year":"2022","unstructured":"Uchino, M. et al. Adherence to eye drops usage in dry eye patients and reasons for non-compliance: A web-based survey. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11020367 (2022).","journal-title":"J. Clin. Med."},{"key":"53334_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237484","author":"LH Tan","year":"2023","unstructured":"Tan, L. H. & Tong, L. The association of dry eye disease with functional visual acuity and quality of life. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12237484 (2023).","journal-title":"J. Clin. Med."},{"key":"53334_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones, L. et al. TFOS DEWS II management and therapy report. Ocul Surf. 15, 575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006 (2017).","journal-title":"Ocul Surf."},{"key":"53334_CR32","doi-asserted-by":"publisher","first-page":"Des36","DOI":"10.1167\/iovs.17-23500","volume":"59","author":"S Koh","year":"2018","unstructured":"Koh, S. Irregular astigmatism and higher-order aberrations in eyes with dry eye disease. Invest. Ophthalmol. Vis. Sci. 59, Des36-des40. https:\/\/doi.org\/10.1167\/iovs.17-23500 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"53334_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100266","volume":"3","author":"R Dong","year":"2023","unstructured":"Dong, R. & Ying, G. S. Characteristics of design and analysis of ophthalmic randomized controlled trials: A review of ophthalmic papers 2020-2021. Ophthalmol. Sci. 3, 100266. https:\/\/doi.org\/10.1016\/j.xops.2022.100266 (2023).","journal-title":"Ophthalmol. Sci."},{"key":"53334_CR34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/jop.2018.0005","volume":"34","author":"I Moon","year":"2018","unstructured":"Moon, I. et al. Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model. J. Ocul. Pharmacol. Ther. 34, 612\u2013620. https:\/\/doi.org\/10.1089\/jop.2018.0005 (2018).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10384-014-0342-4","volume":"58","author":"H Tanioka","year":"2014","unstructured":"Tanioka, H. et al. Expression of the P2Y2 receptor on the rat ocular surface during a 1-year rearing period. Jpn. J. Ophthalmol. 58, 515\u2013521. https:\/\/doi.org\/10.1007\/s10384-014-0342-4 (2014).","journal-title":"Jpn. J. Ophthalmol."},{"key":"53334_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00417-018-3932-x","volume":"256","author":"K Ikeda","year":"2018","unstructured":"Ikeda, K. et al. The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. Graefes Arch. Clin. Exp. Ophthalmol. 256, 739\u2013750. https:\/\/doi.org\/10.1007\/s00417-018-3932-x (2018).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"53334_CR37","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto, Y., Ohashi, Y., Watanabe, H. & Tsubota, K. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: A Japanese phase 2 clinical trial. Ophthalmology 119, 1954\u20131960. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.010 (2012).","journal-title":"Ophthalmology"},{"key":"53334_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12325-019-01188-x","volume":"37","author":"Y Ohashi","year":"2020","unstructured":"Ohashi, Y. et al. Long-term safety and effectiveness of diquafosol for the treatment of dry eye in a real-world setting: A prospective observational study. Adv. Ther. 37, 707\u2013717. https:\/\/doi.org\/10.1007\/s12325-019-01188-x (2020).","journal-title":"Adv. Ther."},{"key":"53334_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2013.09.009","volume":"157","author":"N Yokoi","year":"2014","unstructured":"Yokoi, N., Kato, H. & Kinoshita, S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am. J. Ophthalmol. 157, 85-92.e81. https:\/\/doi.org\/10.1016\/j.ajo.2013.09.009 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"53334_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/jop.2015.0062","volume":"31","author":"KT Nam","year":"2015","unstructured":"Nam, K. T., Ahn, S. M., Eom, Y., Kim, H. M. & Song, J. S. Immediate effects of 3% diquafosol and 0.1% hyaluronic acid ophthalmic solution on tear break-up time in normal human eyes. J. Ocul. Pharmacol. Ther. 31, 631\u2013635. https:\/\/doi.org\/10.1089\/jop.2015.0062 (2015).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/OPTH.S40798","volume":"8","author":"T Kashima","year":"2014","unstructured":"Kashima, T., Hirotaka, I., Hideo, A. & Kishi, S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: A critical appraisal. Clin. Ophthalmol. 8, 1003\u20131010. https:\/\/doi.org\/10.2147\/OPTH.S40798 (2014).","journal-title":"Clin. Ophthalmol."},{"key":"53334_CR42","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/bjophthalmol-2012-302868","volume":"97","author":"H Tanaka","year":"2013","unstructured":"Tanaka, H. et al. Rebamipide increases barrier function and attenuates TNF\u03b1-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br. J. Ophthalmol. 97, 912\u2013916. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302868 (2013).","journal-title":"Br. J. Ophthalmol."},{"key":"53334_CR43","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1089\/jop.2012.0054","volume":"29","author":"M Ueta","year":"2013","unstructured":"Ueta, M., Sotozono, C., Yokoi, N. & Kinoshita, S. Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. J. Ocul. Pharmacol. Ther. 29, 688\u2013693. https:\/\/doi.org\/10.1089\/jop.2012.0054 (2013).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.exer.2008.01.007","volume":"86","author":"JD R\u00edos","year":"2008","unstructured":"R\u00edos, J. D., Shatos, M. A., Urashima, H. & Dartt, D. A. Effect of OPC-12759 on EGF receptor activation, p44\/p42 MAPK activity, and secretion in conjunctival goblet cells. Exp. Eye Res. 86, 629\u2013636. https:\/\/doi.org\/10.1016\/j.exer.2008.01.007 (2008).","journal-title":"Exp. Eye Res."},{"issue":"16","key":"53334_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20164031","volume":"20","author":"C Simsek","year":"2019","unstructured":"Simsek, C., Kojima, T., Nakamura, S., Dogru, M. & Tsubota, K. The effects of rebamipide 2% ophthalmic solution application on murine subbasal corneal nerves after environmental dry eye stress. Int. J. Mol. Sci. 20(16), 4031. https:\/\/doi.org\/10.3390\/ijms20164031 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"53334_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ojo.OJO_29_2017","volume":"11","author":"S Shrivastava","year":"2018","unstructured":"Shrivastava, S., Patkar, P., Ramakrishnan, R., Kanhere, M. & Riaz, Z. Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes. Oman J. Ophthalmol. 11, 207\u2013212. https:\/\/doi.org\/10.4103\/ojo.OJO_29_2017 (2018).","journal-title":"Oman J. Ophthalmol."},{"key":"53334_CR47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","volume":"32","author":"S Koh","year":"2013","unstructured":"Koh, S., Inoue, Y., Sugmimoto, T., Maeda, N. & Nishida, K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea 32, 1219\u20131223. https:\/\/doi.org\/10.1097\/ICO.0b013e318294f97e (2013).","journal-title":"Cornea"},{"key":"53334_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050704","volume":"7","author":"AM Floyd","year":"2012","unstructured":"Floyd, A. M. et al. Mucin deficiency causes functional and structural changes of the ocular surface. PLoS ONE 7, e50704 (2012).","journal-title":"PLoS ONE"},{"key":"53334_CR49","first-page":"114","volume":"28","author":"HJ Lee","year":"2022","unstructured":"Lee, H. J. et al. Diquafosol ophthalmic solution enhances mucin expression via ERK activation in human conjunctival epithelial cells with hyperosmotic stress. Mol. Vis. 28, 114\u2013123 (2022).","journal-title":"Mol. Vis."},{"key":"53334_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3109\/02713683.2014.967871","volume":"40","author":"C Shigeyasu","year":"2015","unstructured":"Shigeyasu, C., Hirano, S., Akune, Y. & Yamada, M. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects. Curr. Eye Res. 40, 878\u2013883. https:\/\/doi.org\/10.3109\/02713683.2014.967871 (2015).","journal-title":"Curr. Eye Res."},{"key":"53334_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/icl.0000000000000558","volume":"45","author":"M Ogawa","year":"2019","unstructured":"Ogawa, M. et al. The effect of rebamipide ophthalmic solution on cytokine and mucin secretion in culture of conjunctival epithelial cells from the Cu, Zn-superoxide dismutase-1 (SOD-1) knock-down mouse. Eye Contact Lens: Sci. Clin. Pract. 45, 93\u201398. https:\/\/doi.org\/10.1097\/icl.0000000000000558 (2019).","journal-title":"Eye Contact Lens: Sci. Clin. Pract."},{"key":"53334_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242617","volume":"15","author":"J Shoji","year":"2020","unstructured":"Shoji, J., Inada, N., Tomioka, A. & Yamagami, S. Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sj\u00f6gren\u2019s syndrome-associated dry eyes. PLoS ONE 15, e0242617. https:\/\/doi.org\/10.1371\/journal.pone.0242617 (2020).","journal-title":"PLoS ONE"},{"key":"53334_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108115","volume":"197","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder, S. C. & Stern, M. E. Biological functions of tear film. Exp. Eye Res. 197, 108115. https:\/\/doi.org\/10.1016\/j.exer.2020.108115 (2020).","journal-title":"Exp. Eye Res."},{"key":"53334_CR54","first-page":"1818","volume":"36","author":"T Inatomi","year":"1995","unstructured":"Inatomi, T., Spurr-Michaud, S., Tisdale, A. S. & Gipson, I. K. Human corneal and conjunctival epithelia express MUC1 mucin. Invest. Ophthalmol. Vis. Sci. 36, 1818\u20131827 (1995).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"53334_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/jop.2011.0142","volume":"28","author":"Y Takeji","year":"2012","unstructured":"Takeji, Y., Urashima, H., Aoki, A. & Shinohara, H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J. Ocul. Pharmacol. Ther. 28, 259\u2013263. https:\/\/doi.org\/10.1089\/jop.2011.0142 (2012).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"53334_CR56","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/s0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall, K., Stevenson, O. D., Mundorf, T. K. & Reis, B. L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107, 631\u2013639. https:\/\/doi.org\/10.1016\/s0161-6420(99)00176-1 (2000).","journal-title":"Ophthalmology"},{"key":"53334_CR57","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/opth.S226168","volume":"13","author":"DE White","year":"2019","unstructured":"White, D. E. et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin. Ophthalmol. 13, 2285\u20132292. https:\/\/doi.org\/10.2147\/opth.S226168 (2019).","journal-title":"Clin. Ophthalmol."},{"key":"53334_CR58","doi-asserted-by":"publisher","DOI":"10.1155\/joph\/6744482","volume":"2025","author":"D Jee","year":"2025","unstructured":"Jee, D., Han, S. Y., Kim, H. S. & Kim, E. C. Comparison of the effect of and compliance with cyclosporine 0.1% after various pretreatments in dry eye disease. J. Ophthalmol. 2025, 6744482. https:\/\/doi.org\/10.1155\/joph\/6744482 (2025).","journal-title":"J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53334-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53334-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53334-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T22:54:17Z","timestamp":1784501657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53334-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53334"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53334-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. RS-2023-00243720), a research grant funded by Kukje Pharmaceuticals Co., Ltd (Grant number: I2203241), and a grant of Korea University Anam Hospital, Seoul, Republic of Korea (K2330791).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22581"}}